Chief Executive Officer
For more than 50 years, Elekta has worked in partnership with our customers to help them fulfill their vital mission to deliver cancer care, and we continue to operate under this principle during COVID-19.
As one of the leading providers of radiation-based cancer treatment solutions, we have developed over the years to become a very strong and international company with very robust business processes and a healthy balance sheet. Our share price enjoyed strong development over the last four years.
Since the outbreak of the coronavirus, the stock markets are strongly reacting and there is a lot of uncertainty. This has affected Elekta’s share price negatively, however, other listed MedTech peers have seen an even harder downturn. Elekta has a strong financial position, global presence and production in several sites, which provide us with a good base to continue with our business even under difficult circumstances.
As clinicians know all too well, cancer does not stop due to the corona crisis. In fact, precision radiation therapy is even more important now because, at the end, it is more cost effective, and our high-precision systems reduce the number of hospital visits as well as the negative side effects on the immune system, which is especially vital now.
We are dedicated to our customers and the patients they treat, so we continue our ongoing installations and service delivery to our installed base in order to help clinicians to keep on fighting cancer. Overall, we are all working to keep the business running during our last months of our fiscal year.
We are starting to see signs of recovery in China, with installations previously delayed, now restarting. In this we can leverage from truly being a global company, and our market-leading position in China and other parts of Asia.
Despite challenging circumstances, we can reaffirm our commitment to be here until cancer isn’t, which will be longer than the coronavirus. We keep thinking forward!